We identified blood mDCs as a cell population of high potential interest in AD progression and treatment, even though future longitudinal studies accompanied by evaluation of biomarkers, like those searching for Aβ and tau proteins in cerebrospinal fluid, and specialized PET and MRI scans may be useful to better understand the meaning of mDC decline in AD clinical course. This evidence concerns the gene MAPT and Alzheimer disease.